Search results for "ADULT"

showing 10 items of 17453 documents

The Italian multiple sclerosis register

2019

The past decade has seen extraordinary increase in worldwide availability of and access to several large multiple sclerosis (MS) databases and registries. MS registries represent powerful tools to provide meaningful information on the burden, natural history, and long-term safety and effectiveness of treatments. Moreover, patients, physicians, industry, and policy makers have an active interest in real-world observational studies based on register data, as they have the potential to answer the questions that are most relevant to daily treatment decision-making. In 2014, the Italian MS Foundation, in collaboration with the Italian MS clinical centers, promoted and funded the creation of the …

Register (sociolinguistics)AdultMaleKnowledge managementDatabases FactualEpidemiologymedia_common.quotation_subjectDisease epidemiologyEpidemiology; Multiple sclerosis; Quality of care; RegisterLongitudinal StudieDermatologyNOCohort StudiesMultiple sclerosisDatabases03 medical and health sciences0302 clinical medicineMultiple SclerosiHumansQuality (business)Longitudinal Studies030212 general & internal medicineRegistriesEpidemiology Multiple sclerosis Quality of care Register Adult Cohort Studies Data Collection Databases Factual Female; Humans Italy; Longitudinal Studies Male Multiple Sclerosis RegistriesQuality of careFactualmedia_commonData collectionbusiness.industryData CollectionQuality of careCorrectionEpidemiology; Multiple sclerosis; Quality of care; Register; Adult; Cohort Studies; Data Collection; Databases Factual; Female; Humans; Italy; Longitudinal Studies; Male; Multiple Sclerosis; RegistriesGeneral MedicineRegisterItalyRegister dataPsychiatry and Mental HealthObservational studyOriginal ArticleSettore MED/26 - NeurologiaFemaleBusinessNeurology (clinical)Cohort Studie030217 neurology & neurosurgeryEpidemiology; Multiple sclerosis; Quality of care; Register; 2708; Neurology (clinical); Psychiatry and Mental Health2708Human
researchProduct

Management of patients with atopic dermatitis undergoing systemic therapy during COVID-19 pandemic in Italy: Data from the DA-COVID-19 registry

2021

Abstract Background Few and small studies have described the management of immunomodulant/immunosuppressive therapies or phototherapy in atopic dermatitis (AD) patients during coronavirus disease 2019 (COVID‐19) pandemic. Methods A national registry, named DA‐COVID‐19 and involving 35 Italian dermatology units, was established in order to evaluate the impact of COVID‐19 pandemic on the management of adult AD patients treated with systemic immunomodulant/immunosuppressive medications or phototherapy. Demographic and clinical data were obtained at different timepoints by teledermatology during COVID‐19 pandemic, when regular visits were not allowed due to sanitary restrictions. Disease severi…

Registrie0301 basic medicineDermatitisSystemic therapy0302 clinical medicinePandemicImmunology and AllergyMedicineRegistriesatopic dermatitis; COVID; SARS‐ CoVCOVIDtreatmentatopic dermatitisatopic dermatitis; COVID; SARS-CoVSARS-CoVAtopic dermatitisDupilumabSARS‐ CoVItalyOriginal ArticleSettore MED/35 - MALATTIE CUTANEE E VENEREEHumanatopic dermatitiAdultmedicine.medical_specialtyTeledermatologyCOVID; SARS‐CoV; atopic dermatitis treatmentCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)ImmunologyCOVID; SARS‐CoV; atopic dermatitis; Adult; Communicable Disease Control; Humans; Italy; Pandemics; Registries; SARS-CoV-2; COVID-19; Dermatitis AtopicAtopicDermatitis Atopic03 medical and health sciencesSettore MED/35Disease severityInternal medicineatopic dermatitis treatmentHumansPandemicsPandemicbusiness.industrySARS-CoV-2SARS‐CoVCOVID-19medicine.disease030104 developmental biology030228 respiratory systemCommunicable Disease Controlatopic dermatitis; COVID; SARS-CoV; Adult; Communicable Disease Control; Humans; Italy; Pandemics; Registries; SARS-CoV-2; COVID-19; Dermatitis Atopicatopic dermatitis COVID SARS-CoVbusiness
researchProduct

Cancer incidence and mortality trends from 2003 to 2014 in Italy.

2019

Objective: To evaluate short-term (2003–2014) cancer incidence and mortality trends in Italy. Methods: Italian Cancer Registries data, available in the AIRTUM database, from 17 out of 20 regions were used. The number of incident cases and deaths were estimated for those registries and those years with incomplete information. Age-standardized rates, overall and stratified by geographic area, region, sex, cancer site, and major age group, were computed. Time trends were expressed as annual percent change of rates. Results: In Italy, among males, incidence rates for all cancers showed during 2003–2014, a significant decrease (−0.9%/year), with stronger reductions in the northwest (−1.3%/year) …

RegistrieAdultMaleCancer ResearchSocio-culturalecancer Epidemiology and prevention incidence Italy mortality time trend03 medical and health sciences0302 clinical medicineNeoplasmscancerMedicineHumans030212 general & internal medicineRegistriesSex DistributionMortality trendsAgedbusiness.industryIncidence (epidemiology)IncidenceCancerGeneral MedicineMiddle Agedmedicine.diseasemortalitytime trendOncologyCancer incidenceItaly030220 oncology & carcinogenesisNeoplasmEpidemiology and preventionFemalebusinessHumanDemographyTumori
researchProduct

Efficacy and safety of tocilizumab in adult-onset Still's disease: Real-life experience from the international AIDA registry

2022

© 2022 Elsevier Inc.Background/objectives: Long-term efficacy and safety of tocilizumab (TCZ) in adult-onset Still's disease (AOSD) mostly derive from small case series. Herein we report a registry-based study investigating TCZ efficacy and safety in a cohort of patients with AOSD evaluated by clinical and serum inflammatory markers as well as drug retention rate analysis. Methods: This is an international multicentre study analyzing data from patients with AOSD regularly enrolled in the AIDA registry. TCZ efficacy was evaluated between baseline and last follow-up assessment in terms of changes in the Pouchot score and laboratory findings. Drug-retention rate was estimated by the Kaplan-Mei…

RegistrieAdultMaleSettore MED/16 - REUMATOLOGIAInterleukin-6Innovative biotechnologiesTocilizumabAdult-onset Still's diseaseAntibodies Monoclonal HumanizedPersonalized medicineAdult-onset Still's disease; Innovative biotechnologies; Interleukin-6; Personalized medicine; TocilizumabSettore MED/38 - Pediatria Generale E SpecialisticaAnesthesiology and Pain MedicineRheumatologyInnovative biotechnologieStill's diseaseHumansFemaleRegistriesImmunotherapyTocilizumab.Still's Disease Adult-OnsetHuman
researchProduct

Survival of 86,690 patients with thyroid cancer: A population-based study in 29 European countries from EUROCARE-5

2017

Background: Incidence rates of thyroid cancer (TC) increased in several countries during the last 30 years, while mortality rates remained unchanged, raising important questions for treatment and follow-up of TC patients. This study updates population-based estimates of relative survival (RS) after TC diagnosis in Europe by sex, country, age, period and histology.Methods: Data from 87 cancer registries in 29 countries were extracted from the EUROCARE-5 dataset. One-and 5-year RS were estimated using the cohort approach for 86,690 adult TC patients diagnosed in 2000-2007 and followed-up to 12/31/2008. RS trends in 1999-2007 and 10-year RS in 2005-2007 were estimated using the period approach…

RegistrieMaleCancer ResearchIMPACTCancer registrie[SDV]Life Sciences [q-bio]Papillary0302 clinical medicineQUALITY-OF-LIFEResidence CharacteristicsAdenocarcinoma FollicularCancer registriesRegistriesThyroid cancerThyroid Neoplasmeducation.field_of_studyRelative survivalIncidence (epidemiology)Mortality rateIncidenceDiagnosis-Related GroupCancer registries; EUROCARE; Europe; Papillary; Relative survival; Thyroid cancer; Adenocarcinoma Follicular; Adolescent; Adult; Aged; Carcinoma; Carcinoma Papillary; Diagnosis-Related Groups; Europe; Female; Humans; Incidence; Male; Middle Aged; Registries; Residence Characteristics; Sex Distribution; Thyroid Neoplasms; Young Adult; Oncology; Cancer ResearchMiddle AgedPREVALENCE3. Good healthEuropeOncologyThyroid Cancer Papillary030220 oncology & carcinogenesisCohortFemaleEUROCAREHumanAdultmedicine.medical_specialtyAdolescentPopulationGEOGRAPHICAL-DISTRIBUTIONUNITED-STATESSocio-culturale030209 endocrinology & metabolismAdenocarcinomaRelative survivalThyroid cancerRECENT TRENDS03 medical and health sciencesYoung AdultMANAGEMENTmedicineHumansThyroid NeoplasmsSex DistributioneducationSurvival rateDiagnosis-Related GroupsAgedbusiness.industryMORTALITYCarcinomaFollicularCancer registries; EUROCARE; Europe; Papillary; Relative survival; Thyroid cancer; Oncology; Cancer Researchmedicine.diseaseCarcinoma PapillaryCancer registrySurgeryMICROCARCINOMAResidence CharacteristicCancer registries ; EUROCARE ; Europe ; Papillary ; Relative survival ; Thyroid cancerbusinessDemography
researchProduct

Increased thyroid cancer incidence in a basaltic volcanic area is associated with non-anthropogenic pollution and biocontamination

2016

The increased thyroid cancer incidence in volcanic areas suggests an environmental effect of volcanic-originated carcinogens. To address this problem, we evaluated environmental pollution and biocontamination in a volcanic area of Sicily with increased thyroid cancer incidence. Thyroid cancer epidemiology was obtained from the Sicilian Regional Registry for Thyroid Cancer. Twenty-seven trace elements were measured by quadrupole mass spectrometry in the drinking water and lichens (to characterize environmental pollution) and in the urine of residents (to identify biocontamination) in the Mt. Etna volcanic area and in adjacent control areas. Thyroid cancer incidence was 18.5 and 9.6/10(5) inh…

RegistrieMaleEpidemiologyEndocrinology Diabetes and MetabolismEnvironmental pollution010501 environmental sciences01 natural sciencesSettore MED/13 - Endocrinologia0302 clinical medicineEndocrinologyAdenocarcinoma FollicularRegistriesLichenThyroid cancerSicilyThyroid NeoplasmCadmiumgeography.geographical_feature_categoryIncidenceThyroidEnvironmental exposureMiddle AgedHeavy metalmedicine.anatomical_structure030220 oncology & carcinogenesisEnvironmental chemistryTrace elementFemaleHumanAdultMineralogychemistry.chemical_elementVolcanic EruptionsThyroid cancer03 medical and health sciencesmedicineHumansThyroid Neoplasms0105 earth and related environmental sciencesAgedCross-Sectional StudiegeographyTrace elementsVolcanic areaDrinking WaterEnvironmental Exposuremedicine.diseaseCarcinoma PapillaryMercury (element)Cross-Sectional StudieschemistryVolcanoEnvironmental scienceThyroid cancer; Volcanic area; Trace elementsEnvironmental Pollution
researchProduct

Years of life that could be saved from prevention of hepatocellular carcinoma

2016

Summary Background Hepatocellular carcinoma (HCC) causes premature death and loss of life expectancy worldwide. Its primary and secondary prevention can result in a significant number of years of life saved. Aim To assess how many years of life are lost after HCC diagnosis. Methods Data from 5346 patients with first HCC diagnosis were used to estimate lifespan and number of years of life lost after tumour onset, using a semi-parametric extrapolation having as reference an age-, sex- and year-of-onset-matched population derived from national life tables. Results Between 1986 and 2014, HCC lead to an average of 11.5 years-of-life lost for each patient. The youngest age-quartile group (18–61 y…

RegistrieMalePediatricsDatabases FactualHepatocellular carcinoma0302 clinical medicineprevention80 and overSecondary PreventionPharmacology (medical)Prospective StudiesRegistriesYoung adultProspective cohort studySecondary preventionAged 80 and overeducation.field_of_studyLiver NeoplasmsGastroenterologyDisease ManagementMiddle AgedPrimary PreventiondiagnosiItalyLiver Neoplasm030220 oncology & carcinogenesisHepatocellular carcinoma030211 gastroenterology & hepatologyFemaleHumanAdultmedicine.medical_specialtyCarcinoma HepatocellularAdolescentPopulationlife expentancyMilan criteria03 medical and health sciencesDatabasesYoung AdultLife ExpectancymedicineHumansAdolescent; Adult; Aged; Aged 80 and over; Carcinoma Hepatocellular; Databases Factual; Disease Management; Female; Humans; Italy; Life Expectancy; Liver Neoplasms; Male; Middle Aged; Primary Prevention; Prospective Studies; Registries; Secondary Prevention; Young Adult; Pharmacology (medical)educationFactualAgedHepatologybusiness.industryCarcinomaSettore MED/09 - MEDICINA INTERNAHepatocellularmedicine.diseaseSurgeryProspective StudieYears of potential life lostLife expectancybusiness
researchProduct

Bleeding symptoms at disease presentation and prediction of ensuing bleeding in inherited FVII deficiency.

2012

SummaryIndividuals with inherited factor VII (FVII) deficiency display bleeding phenotypes ranging from mild to severe, with 30% of patients having always been asymptomatic (non-bleeding). In 626 FVII-deficient individuals, by analysing data from the International Factor VII (IF7) Registry and the Seven Treatment Evaluation Registry (STER), we determined whether bleeding type at disease presentation and FVII coagulant activity (FVIIc) predict ensuing bleeds. At disease presentation/diagnosis, 272 (43.5%) individuals were non-bleeding, 277 (44.2%) had minor bleeds, and 77 (12.3%) had major bleeds. During a median nine-year index period (IP) observation, 87.9% of non-bleeding individuals at p…

RegistrieMalePediatricsFactor VII DeficiencyInternational CooperationAsymptomatic individual030204 cardiovascular system & hematologychemistry.chemical_compound0302 clinical medicineRetrospective StudieAge FactorRegistriesYoung adultChildClinical Trials as TopicHematologyFactor VIIAge FactorsHematologyFactor VIIMiddle AgedPhenotypeTreatment OutcomeChild PreschoolFemalePresentation (obstetrics)medicine.symptomHumanAdultQuality ControlRiskmedicine.medical_specialtyAdolescentHemorrhageAsymptomaticMajor bleed03 medical and health sciencesYoung AdultInternal medicinemedicineHumansRetrospective StudiesModels Statisticalbusiness.industryMinor bleedInfantRetrospective cohort studychemistryDisease PresentationRelative riskbusiness030215 immunologyThrombosis and haemostasis
researchProduct

Incidence and prognostic factors related to major adverse cerebrovascular events in patients with complex aortic diseases treated by the chimney tech…

2018

Abstract Objective Endovascular aneurysm repair (EVAR) with the chimney technique (ch-EVAR) has been used for the treatment of aortic aneurysms as an alternative approach to fenestrated endografting or open repair. Nonetheless, the need for an upper extremity arterial access may contribute to a higher risk for periprocedural cerebrovascular events. This study reports on the perioperative cerebral and major adverse cardiac and cerebrovascular events (MACCE) after ch-EVAR. Methods The PERICLES registry (PERformance of the chImney technique for the treatment of Complex aortic pathoLogiES) is an international, retrospective multicenter study evaluating the performance of ch-EVAR for the treatme…

RegistrieMaleTime Factorsmedicine.medical_treatment030204 cardiovascular system & hematologySettore MED/22 - Chirurgia VascolareEndovascular aneurysm repair0302 clinical medicineRetrospective StudieRisk FactorsCause of DeathCarotid artery diseaseOdds RatioRegistries030212 general & internal medicineMultivariate AnalysiStrokeCause of deathAged 80 and overIncidenceEndovascular ProceduresAtrial fibrillationchimney technique; stroke; aortic archMiddle AgedStrokeHeart DiseaseTreatment OutcomeIschemic Attack TransientCerebrovascular DisorderCardiologyFemaleCardiology and Cardiovascular MedicineHumanAdultmedicine.medical_specialtyAcute coronary syndromeLogistic ModelTime FactorHeart DiseasesOperative TimeAortic DiseasesBlood Vessel Prosthesis Implantation03 medical and health sciencesInternal medicinemedicineHumanscardiovascular diseasesAgedRetrospective StudiesEndovascular ProcedureChi-Square Distributionbusiness.industryRisk FactorOdds ratioPerioperativeAortic Diseasemedicine.diseaseSurgeryCerebrovascular DisordersLogistic ModelsMultivariate AnalysisSurgerybusiness
researchProduct

Efficacy and safety of rituximab with and without methotrexate in the treatment of rheumatoid arthritis patients: Results from the GISEA register

2014

Abstract Introduction Rituximab (RTX) is a monoclonal anti-CD20 antibody approved for the treatment of rheumatoid arthritis (RA) in association with methotrexate (MTX). Objectives To evaluate the efficacy and safety of RTX–MTX combination therapy compared with RTX alone in the treatment of RA. Methods We analyzed data from a prospective cohort study, the Italian biologic register GISEA, to investigate the efficacy and safety of rituximab. Moreover, the adverse events (AE) and the causes of discontinuation therapy were analyzed. Results We identified 338 RA patients, 162 treated with RTX and 176 with RTX–MTX. After 52 and 104 weeks of therapy the disease activity score in 28 joints and the H…

RegistrieMaleanti-CD20 rituximab; rheumatoid arthritis; GISEArheumatoid arthritisSettore MED/16 - REUMATOLOGIAAnti-CD20Arthritis RheumatoidAntibodies Monoclonal Murine-DerivedRheumatoidMonoclonalRegistriesProspective cohort studyGISEAAnti-CD20; Methotrexate; Rheumatoid arthritis; Rituximab; Adult; Aged; Antibodies Monoclonal; Antibodies Monoclonal Murine-Derived; Antirheumatic Agents; Arthritis Rheumatoid; Drug Therapy Combination; Female; Humans; Male; Methotrexate; Middle Aged; Treatment Outcome; RegistriesAntirheumatic AgentAntibodies MonoclonalMiddle AgedTreatment OutcomeRituximab rheumatoid arthritisAntirheumatic AgentsRheumatoid arthritisCombinationMonoclonalDrug Therapy CombinationFemaleRituximabRituximabHumanmedicine.drugmusculoskeletal diseasesAdultMurine-Derivedmedicine.medical_specialtyCombination therapyAntibodiesNOAnti-CD20; Methotrexate; Rheumatoid arthritis; RituximabDrug TherapyRheumatologyanti-CD20 rituximabInternal medicinemedicineHumansRheumatoid arthritisAdverse effectRheumatoid arthritiAnti-CD20; Methotrexate; Rheumatoid arthritis; Rituximab; Adult; Aged; Antibodies Monoclonal; Antibodies Monoclonal Murine-Derived; Antirheumatic Agents; Arthritis Rheumatoid; Drug Therapy Combination; Female; Humans; Male; Methotrexate; Middle Aged; Rituximab; Treatment Outcome; Registries; RheumatologyAgedbusiness.industryArthritismedicine.diseaseSurgeryDiscontinuationMethotrexateMethotrexatebusinessJoint Bone Spine
researchProduct